162 related articles for article (PubMed ID: 2120486)
1. Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.
Min WK; Kim YB; Lee KM
Korean J Ophthalmol; 1990 Jun; 4(1):12-5. PubMed ID: 2120486
[TBL] [Abstract][Full Text] [Related]
2. Repetitive low-dose tissue plasminogen activator for the clearance of experimental vitreous hemorrhage.
Min WK; Kim YB; Ahn BH; Seong GH
Korean J Ophthalmol; 1994 Dec; 8(2):45-8. PubMed ID: 7853730
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal tissue plasminogen activator treatment of experimental vitreous hemorrhage.
Johnson RN; Olsen KR; Hernandez E
Arch Ophthalmol; 1989 Jun; 107(6):891-4. PubMed ID: 2499298
[TBL] [Abstract][Full Text] [Related]
4. Repetitive, low-dose tissue plasminogen activator for clearance of experimental vitreous hemorrhage.
Zhao P; Wang W; Song H; Zhu Y
Yan Ke Xue Bao; 1995 Mar; 11(1):29-31, 40. PubMed ID: 8575602
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage.
Coll GE; Sparrow JR; Marinovic A; Chang S
Retina; 1995; 15(4):319-26. PubMed ID: 8545578
[TBL] [Abstract][Full Text] [Related]
6. Resolution of experimental intravitreal fibrin by tissue plasminogen activator.
Min WK; Kim YB
Korean J Ophthalmol; 1990 Dec; 4(2):58-65. PubMed ID: 2128708
[TBL] [Abstract][Full Text] [Related]
7. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.
Kamei M; Misono K; Lewis H
Am J Ophthalmol; 1999 Dec; 128(6):739-46. PubMed ID: 10612511
[TBL] [Abstract][Full Text] [Related]
8. Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy.
Hesse L; Nebeling B; Schroeder B; Heller G; Kroll P
Exp Eye Res; 2000 Jan; 70(1):31-9. PubMed ID: 10644418
[TBL] [Abstract][Full Text] [Related]
9. Use of tissue plasminogen activator in experimental hyphema.
Lambrou FH; Snyder RW; Williams GA
Arch Ophthalmol; 1987 Jul; 105(7):995-7. PubMed ID: 3111453
[TBL] [Abstract][Full Text] [Related]
10. Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery.
Murray TG; Jaffe GJ; McKay BS; Han DP; Burke JM; Abrams GW
Refract Corneal Surg; 1992; 8(1):44-8; discussion 48-53. PubMed ID: 1554639
[TBL] [Abstract][Full Text] [Related]
11. Management of postvitrectomy diabetic vitreous hemorrhage with tissue plasminogen activator (t-PA) and volume homeostatic fluid-fluid exchanger.
Wu WC; Chang SM; Chen JY; Chang CW
J Ocul Pharmacol Ther; 2001 Aug; 17(4):363-71. PubMed ID: 11572467
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal tPA and SF6 promote clearing of premacular subhyaloid hemorrhages in shaken and battered baby syndrome.
Conway MD; Peyman GA; Recasens M
Ophthalmic Surg Lasers; 1999 Jun; 30(6):435-41. PubMed ID: 10392730
[TBL] [Abstract][Full Text] [Related]
13. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes.
Hrach CJ; Johnson MW; Hassan AS; Lei B; Sieving PA; Elner VM
Arch Ophthalmol; 2000 May; 118(5):659-63. PubMed ID: 10815158
[TBL] [Abstract][Full Text] [Related]
14. The role of intravitreal bevacizumab in experimental posterior penetrating eye injury.
Mehdizadeh M; Fattahi F; Eghtedari M; Nowroozzadeh MH; Toosi F
Retina; 2011 Jan; 31(1):154-60. PubMed ID: 20838359
[TBL] [Abstract][Full Text] [Related]
15. Induction of Posterior Vitreous Detachment in Pediatric Vitrectomy by Preoperative Intravitreal Injection of Tissue Plasminogen Activator.
Chuang CC; Chen SN
J Pediatr Ophthalmol Strabismus; 2016; 53(2):113-8. PubMed ID: 27018884
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal tissue plasminogen activator to treat refractory diabetic macular edema by induction of posterior vitreous detachment.
Abrishami M; Moosavi MN; Shoeibi N; Hosseinpoor SS
Retina; 2011 Nov; 31(10):2065-70. PubMed ID: 21983248
[TBL] [Abstract][Full Text] [Related]
17. The use of intravitreal tissue plasminogen activator in the treatment of experimental subretinal hemorrhage in the pig model.
Boone DE; Boldt HC; Ross RD; Folk JC; Kimura AE
Retina; 1996; 16(6):518-24. PubMed ID: 9002136
[TBL] [Abstract][Full Text] [Related]
18. Treatment of experimental intravitreal fibrin with tissue plasminogen activator.
Lambrou FH; Snyder RW; Williams GA; Lewandowski M
Am J Ophthalmol; 1987 Dec; 104(6):619-23. PubMed ID: 3120591
[TBL] [Abstract][Full Text] [Related]
19. The effect of tissue plasminogen activator on retinal bleeding.
Sternberg P; Aguilar HE; Drews C; Aaberg TM
Arch Ophthalmol; 1990 May; 108(5):720-2. PubMed ID: 2110447
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
Diakonis VF; Tsourdou A; Tzatzarakis MN; Tsika C; Charisis S; Naoumidi I; Plainis S; Tsilimbaris MK
J Ocul Pharmacol Ther; 2013 Sep; 29(7):627-32. PubMed ID: 23556534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
